



FEATURED OPTIONS RADAR REPORT



Curis Calls Position for Catalyst-Rich Year

Ticker/Price: CRIS (\$10.95)

Analysis:

Curis (CRIS) on 3/12 traded 9000 calls which is 5X daily average and nearly all of the action in the final fifteen minutes of the session with a block of 5000 June \$15 calls bought \$2.35, the June \$12.50 calls with 1000 bought, and 500 September \$17.5 calls bought for \$2.65 offer to open. CRIS already has over 3500 June \$10 calls and 4250 June \$15 calls in open interest from buyers and a lot of March open interest into expiration week. CRIS has based much of 2021 and pulled back well off January highs but put in a strong candle last week as it starts to work out of its pullback trend. CRIS is a Biotech focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. CRIS has several therapeutics in the pipeline, CA-4948, which is being tested in a Phase 1 dose escalating clinical trial in patients with non-Hodgkin lymphomas, including those with Myeloid Differentiation Primary Response Protein 88, or MYD88 alterations; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation, or VISTA signaling pathway; Fimepinostat, which is currently being explored in clinical studies in patients with MYC-altered diffuse large B-cell lymphoma, or DLBCL and solid tumors and has been granted Orphan Drug Designation and Fast Track Designation for the treatment of DLBCL by the U.S. Food and Drug Administration. CRIS also has CA-170 and CA-327 in the pipeline. CRIS has a market cap of \$866.5M with minimal current revenues. Analysts have an average target of \$15.75 and short interest elevated at 14.5% of the float. HC Wainwright raised its target to \$16 in January seeing several catalysts for CA-4948 in 2021. Cantor raised its target to \$15 in December following positive CA-4948 data in AML/MDS that showed a high response rate. CRIS has the potential for two novel therapeutics for three potential indications that all could have peak sales over \$1B if successfully developed. RA Capital, Point-72, and Healthcor were all buyers of the stock last quarter.

Hawk Vision:



Hawk's Perspective: CRIS clearly is a more speculative name but looks good from all angles here with the chart, options action, and potential valuation disconnect if successful.

Confidence Ranking: \$\$